Credit Suisse Ag Cerevel Therapeutics Holdings, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 111,634 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

111,634

Previous 174,498 36.03%

Holding current value

Previous $7.4 Million 36.23%

% of portfolio

0.0%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$40.88 - $43.27 $2.57 Million - $2.72 Million	-62,864 Reduced 36.03%	111,634 $4.72 Million
Q4 2023 Feb 08, 2024	BUY	$20.27 - $42.44 $2.29 Million - $4.79 Million	112,924 Added 183.4%	174,498 $7.4 Million
Q3 2023 Nov 13, 2023	SELL	$20.26 - $31.91 $226,891 - $357,360	-11,199 Reduced 15.39%	61,574 $1.34 Million
Q2 2023 Aug 11, 2023	BUY	$23.9 - $35.38 $413,565 - $612,215	17,304 Added 31.2%	72,773 $2.31 Million
Q1 2023 May 10, 2023	BUY	$22.82 - $35.32 $387 - $600	17 Added 0.03%	55,469 $1.35 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $137,295 - $173,095	5,416 Added 10.82%	55,452 $1.75 Million
Q3 2022 Nov 10, 2022	BUY	$25.5 - $41.42 $39,091 - $63,496	1,533 Added 3.16%	50,036 $1.42 Million
Q2 2022 Aug 12, 2022	BUY	$20.62 - $37.15 $239,645 - $431,757	11,622 Added 31.51%	48,503 $1.28 Million
Q1 2022 May 16, 2022	BUY	$23.5 - $35.38 $115,620 - $174,069	4,920 Added 15.39%	36,881 $1.29 Million
Q4 2021 Feb 14, 2022	BUY	$29.21 - $44.64 $130,393 - $199,272	4,464 Added 16.23%	31,961 $1.04 Million
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $260,116 - $475,329	12,235 Added 80.17%	27,497 $811,000
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $29,076 - $68,732	2,315 Added 17.88%	15,262 $391,000
Q1 2021 May 14, 2021	BUY	$12.37 - $17.74 $160,154 - $229,679	12,947 New	12,947 $178,000

Others Institutions Holding CERE

# of Institutions

Shares Held

5.93M

Call Options Held

27.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account